Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.

The agency advises patients to confirm that any cell, gene, or tissue therapy they receive is approved by a regulator or authorized for use in a clinical trial.

By correcting for ancestral bias in publicly available datasets, PhyloFrame produces better outcomes predictions for under-sampled populations.

Coeptis previously held limited co-development rights to GEAR. In conjunction with the new license agreement, Coeptis has formed a majority-owned subsidiary, called GEAR Therapeutics, to evaluate GEAR ...

Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, ...

The Rome-based charity recently applied for marketing authorization of the same gene therapy, previously advanced by Orchard Therapeutics, in the EU.

The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

ElevateBio has entered into a multi-year collaboration with Amazon's cloud arm to identify treatment targets and new CRISPR systems.

NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...